Loading clinical trials...
Loading clinical trials...
Convalescent Plasma to Stem Coronavirus: A Randomized, Blinded Phase 2 Study Comparing the Efficacy and Safety Human Coronavirus Immune Plasma (HCIP) vs. Control (SARS-CoV-2 Non-immune Plasma) Among Adults Exposed to COVID-19
Conditions
Interventions
Anti- SARS-CoV-2 Plasma
SARS-CoV-2 non-immune Plasma
Locations
25
United States
University of Alabama at Birmingham
Birmingham, Alabama, United States
Center for American Indian Health - Whiteriver Office
Whiteriver, Arizona, United States
University of California, San Diego
La Jolla, California, United States
University of California, Los Angeles
Los Angeles, California, United States
University of California, Irvine Health
Orange, California, United States
Western Connecticut Health Network, Danbury Hospital
Danbury, Connecticut, United States
Start Date
June 10, 2020
Primary Completion Date
April 22, 2021
Completion Date
June 22, 2021
Last Updated
April 26, 2022
NCT06631287
NCT04327570
NCT04772170
NCT04885504
NCT06099795
NCT04510025
Lead Sponsor
Johns Hopkins University
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions